Axogen Expands Surgical Portfolio with Acquisition of Innovative Sutureless Nerve Repair Device
Axogen has completed its acquisition of BioCircuit Technologies and its NerveTape technology, the first FDA-cleared device enabling sutureless repair of peripheral nerves. The innovation simplifies nerve repair procedures compared to traditional microsuturing techniques and is expected to generate approximately $6 million in revenue during the fourth quarter of 2026. The acquisition aligns with Axogen's mission to establish peripheral nerve repair as a standard surgical practice.
Axogen's acquisition integrates NerveTape into a comprehensive peripheral nerve repair portfolio that already includes allograft products and protective devices. The technology represents a shift in surgical methodology—moving away from the precision suturing techniques that have traditionally dominated nerve reconnection procedures. This expansion allows Axogen to address multiple repair scenarios through different technological approaches within a single organization.
The financial projections reveal significant growth expectations, with BioCircuit contributing $6 million in the final quarter of 2026 and escalating to $34 million throughout 2027. These figures were not factored into Axogen's existing annual guidance, suggesting the acquisition unlocks new revenue streams. The company maintains confidence in achieving its gross margin and cash flow targets despite this major integration.
This acquisition could reshape accessibility to nerve repair options for patients with traumatic injuries or surgical complications affecting nerve function. By simplifying repair procedures, NerveTape may reduce operative time and technical barriers for surgeons, potentially expanding which healthcare facilities can offer these interventions. However, market adoption will depend on surgeon training, reimbursement policies, and clinical outcomes data demonstrating advantages over established microsuturing methods.